Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma

Annals of Surgery

Volumn 242, Issue 1, 2005, Pages 55-63

  Ren, Yi ^a   Law, Simon ^a   Huang, Xin ^a   Lee, Ping Yin ^a   Bacher, Michael ^a   Srivastava, Gopesh ^b   Wong, John ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CARCINOGENESIS; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR DIFFERENTIATION; TUMOR GROWTH;

BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; LYMPH NODES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 21444435187     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000168555.97710.bb     Document Type: Article

References (42)

1. Law S, Kwong DL, Kwok KF, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238: 339-348.
2. Siewert JR, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353-361.
3. Furihata M, Ohtsuki Y, Ogoshi S, et al. Prognostic significance of human papillomavirus genomes (type-16, -18) and aberrant expression of p53 protein in human esophageal cancer. Int J Cancer. 1993;54:226-230.
4. Nishihira T, Hashimoto Y, Katayama M, et al. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol. 1993;119: 441-449.
5. Lam KY, Law S, Tin L, et al. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am J Gastroenterol. 1999;94:2060-2068.
6. Lam KY, Tsao SW, Zhang D, et al. Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinico-pathological study and survival analysis of 70 patients. Int J Cancer. 1997;74:212-219.
7. Lam KY, Law SY, So MK, et al. Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma. Cancer. 1996;77:7-13.
8. Bernhagen J, Calandra T, Mitchell RA, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993;365:756-759.
9. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995;377:68-71.
10. Donnelly SC, Haslett C, Reid PT, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med. 1997;3:320-323.
11. Mikulowska A, Metz CN, Bucala R, et al. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol. 1997;158:5514-5517.
12. Lan HY, Yang N, Nikolic-Paterson DJ, et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int. 2000;57:499-509.
13. Lan HY, Yang N, Brown FG, et al. Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation. 1998;66:1465-1471.
14. Brown FG., Nikolic-Paterson DJ, Metz C, et al. Up-regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat. Clin Exp Immunol. 1999;118:329-336.
15. Lin SG, Yu XY, Chen YX, et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res. 2000; 87:1202-1208.
16. Calandra T, Bernhagen J, Mitchell RA, et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994;179:1895-1902.
17. Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000;10: 359-366.
18. Hudson JD, Shoaibi MA, Maestro R, et al. Proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190:1375-1382.
19. Shimizu T, Abe R, Nakamura H, et al. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun. 1999;264:751-758.
20. Bini L, Magi B, Marzocchi B, et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis. 1997;18:2832-2841.
21. Meyer-Siegler K, Hudson PB. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology. 1996;48:448-452.
22. Kamimura A, Kamachi M, Nishihira J, et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 2000;89:334-341.
23. Ren Y, Tsui HT, Poon RTP, et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer. 2003;107:22-29.
24. Arenberg DA, Kunkel SL, Polverini PJ, et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996;97:2792-2802.
25. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
26. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001;233:227-235.
27. Ogawa H, Nishihira J, Sato Y, et al. An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine. 2000;12:309-314.
28. Sobin LH. TNM classification: clarification of number of regional lymph nodes for pNO. Br J Cancer. 2001;85:780.
29. Hu Y, Lam KY, Wan TS, et al. Establishment and characterization of HKESC-1, a new cancer cell line from human esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 2000;118:112-120.
30. Hu YC, Lam KY, Law SY, et al. Establishment, characterization, karyotyping, and comparative genomic hybridization analysis of HKESC-2 and HKESC-3: two newly established human esophageal squamous cell carcinoma cell lines. Cancer Genet Cytogenet. 2002;135: 120-127.
31. Ohno S, Tachibana M, Shibakita M, et al. Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer. Ann Surg Oncol. 2000;7:750-757.
32. Barnas C, Martel-Planche G, Furukawa Y, et al. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer. 1997;71:79-87.
33. Shibakita M, Tachibana M, Dhar DK, et al. Spontaneous apoptosis in advanced esophageal carcinoma: its relation to Fas expression. Clin Cancer Res. 2000;6:4755-4759.
34. Tezuka Y, Yonezawa S, Maruyama I, et al. Expression of thrombo-modulin in esophageal squamous-cell carcinoma and its relationship to lymph-node metastasis. Cancer Res. 1995;55:4196-4200.
35. Inoue K, Ozeki Y, Suganuma T, et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma: association with angiogenesis and tumor progression. Cancer. 1997;79:206-213.
36. Shih CH, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000;6:1161-1168.
37. Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer. 2001;92:663-669.
38. Kitada Y, Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer. 2001;93:662-666.
39. Schadendorf D, Moller A, Algermissen B, et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol. 1993;151:2667-2675.
40. Chesney J, Metz C, Bacher M., et al. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 1999;5:181-191.
41. Yang Y, Degranpre P, Kharfi A, et al. Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. J Clin Endocrinol Metab. 2000;85:4721-4727.
42. Kitadai Y, Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int. J. Cancer 2001;93:662-666.